RXRX

Recursion Pharmaceuticals (RXRX) fell 8.03% in the latest trading session, significantly underperforming the S&P 500's 0.06% decline. Despite a 36.25% gain over the past month, the stock has received a Zacks Rank #4 (Sell) rating.

The company faces headwinds with consensus EPS estimates revised 2.17% lower over the past month, though revenue projections show growth. The biotech sector itself ranks in the bottom 33% of industries.

Recursion Pharmaceuticals (RXRX) declined 3.14% to $4.63 on October 6, 2026, underperforming the broader market which gained modestly. Despite a strong 31.68% monthly gain, the stock fell as the S&P 500 rose 0.58%.

The company is expected to report an EPS of -$0.24 with revenue of $8.42 million, showing improvement year-over-year. RXRX holds a Zacks Rank #3 (Hold) rating with recent downward EPS estimate revisions.